Combination of platelet-rich plasma with polycaprolactone-tricalcium phosphate scaffolds for segmental bone defect repair
Combination of platelet-rich plasma with polycaprolactone-tricalcium phosphate scaffolds for segmental bone defect repair
复制标题
DOI：
10.1002/jbm.a.31142
复制
发表时间：
2007-06-15
影响因子：
4.9
通讯作者：
Guldberg, Robert E.
中科院分区：
文献类型：
--
作者：
Rai, Bina;Oest, Megan E.;Guldberg, Robert E.
多孔支架生物材料可以提供骨移植的临床替代方案；然而，单独的支架通常不足以治愈大的骨缺损。大量研究表明，骨诱导生长因子或基因传递可显着改善骨修复。然而，考虑到血管化在骨再生过程中的重要作用，将促进血管向内生长的因素纳入结构中也可能是有益的。在这项研究中，测试了将结构性聚己内酯-20%磷酸三钙（PCL-TCP）复合支架与富血小板血浆（PRP）相结合的策略。将构建体双侧植入 8 mm 大鼠不愈合股骨缺损后，使用对比增强微计算机断层扫描 (micro-CT) 成像在第 3 周和第 12 周对 3D 血管和骨向内生长进行量化。第 3 周时，PRP 治疗股骨的血管体积分数比对照股骨高 70.3%。有趣的是，空支架组在早期时间点的骨体积分数（BVF）显着较高。第 12 周时，两组之间的 BVF 测量结果在统计学上相当。然而，与空支架对照组 (33%) 相比，经过 PRP 治疗的股骨 (83%) 实现骨愈合的比例更高。与这一观察结果一致，功能整合的生物力学评估也显示，与空支架相比，经 PRP 处理的缺陷观察到的扭转刚度显着更高。然而，失效时的极限扭矩并未得到改善，这可能是由于支架材料的缓慢吸收特性所致。组织学评估显示两组中血管化结缔组织和骨的浸润。鉴于该模型中未经治疗的缺损中骨向内生长的情况很少，PCL-TCP 支架显然能够促进骨向内生长，但未能始终如一地桥接缺损。在 PCL-TCP 支架中添加 PRP 可加速早期血管向内生长并改善长期功能整合。综上所述，本研究的结果表明，单独使用 PRP 或与其他生物活性成分结合使用，可能是增强多孔生物材料支架修复原位缺陷能力的有效方法。 (c) 2007 年 Wiley periodicals, Inc. J Biomed Mater Res 81A: 888-899, 2007。
Porous scaffold biomaterials may offer a clinical alternative to bone grafts; however, scaffolds alone are typically insufficient to heal large bone defects. Numerous studies have demonstrated that osteoinductive growth factor or gene delivery significantly improves bone repair. However, given the important role of vascularization during bone regeneration, it may also be beneficial to incorporate factors that promote vascular ingrowth into constructs. In this study, a strategy combining structural polycaprolactone-20% tricalcium phosphate (PCL-TCP) composite scaffolds with platelet-rich plasma (PRP) was tested. Following bilateral implantation of constructs into 8 mm rat nonunion femoral defects, 3D vascular and bone ingrowth were quantified at 3 and 12 weeks using contrast-enhanced microcomputed tomography (micro-CT) imaging. At week 3, PRP-treated femurs displayed 70.3% higher vascular volume fraction than control femurs. Interestingly, bone volume fraction (BVF) was significantly higher for the empty scaffold group at the early time point. At 12 weeks, BVF measurements between the two groups were statiscally equivalent. However, a greater proportion of PRP-treated femurs (83%) achieved bone union as compared to empty scaffold controls (33%). Consistent with this observation, biomechanical evaluation of functional integration also revealed a significantly higher torsional stiffness observed for PRP-treated defects compared to empty scaffolds. Ultimate torque at failure was not improved, however, perhaps due to the slow resorption profile of the scaffold material. Histological evaluation illustrated infiltration of vascularized connective tissue and bone in both groups. Given that bone ingrowth into untreated defects in this model is minimal, PCL-TCP scaffolds were clearly able to promote bone ingrowth but failed to consistently bridge the defect. The addition of PRP to PCL-TCP scaffolds accelerated early vascular ingrowth and improved longer-term functional integration. Taken together, the results of this study suggest that the use of PRP, alone or in combination with other bioactive components, may be an effective approach to augment the ability of porous biomaterial scaffolds to repair orthotopic defects. (c) 2007 Wiley Periodicals, Inc. J Biomed Mater Res 81A: 888-899, 2007.